A Hard Look: How Did China Pharma Growth Fall So Fast, So Steeply?
This article was originally published in PharmAsia News
While many are still shocked by the double-digit drop in quarterly pharma sales in the world’s second-largest economy, the underlying factors for the fast deterioration in China have in fact been brewing for some time and are multi-faceted, Yang Dongsheng of the R&D based Pharmaceutical Association Committee (RDPAC) tells PharmAsia News in an exclusive interview.
You may also be interested in...
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.
China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.
After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for Celgene's Abraxane to supply China.